ClinicalTrials.gg
TerminatedNCT03342417Updated Nov 9, 2021

Combination of Nivolumab and Ipilimumab in Breast, Ovarian and Gastric Cancer Patients

A Phase 2 interventional study of Nivolumab and Ipilimumab in Breast Cancer Female, Ovarian Cancer and Gastric Cancer, sponsored by ExcellaBio LLC. Terminated at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-11-09.

Sponsored by ExcellaBio LLC · Phase 2, Interventional, and Treatment

Why this study was terminated
Slow patient accrual

From the registry’s dates

  • Primary completion was May 2019, 7 years 5 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
5
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,779 studies in Ovarian Neoplasms with a site in United States — 278 open to participants now, 454 under way, 46 of them phase 3. Ovarian Neoplasms · United States.

Enrollment
1,380th of 1,498
5 · median 47
Started
2018
with 75 others
Phase 2
485 of 1,779
53 open now
Registered
1,078th of 1,779
by date

Among the 1,779 studies in Ovarian Neoplasms with a site in United States, this one is the 1,380th largest by enrollment of the 1,498 interventional ones that give a count, is one of 76 that started in 2018, is one of 485 in phase 2, and was the 1,078th registered.

Ovarian Neoplasms

3,387 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

278 of the 1,779 studies in Ovarian Neoplasms with a site in United States are open now. Recruiting first, the newest first:

273 more — sign in →

All 278 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 602 Ovarian Neoplasms studies recruiting now, 439 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,779 studies in Ovarian Neoplasms with a site in United States, or all of them as a file.
02

Study summary

Safety and tolerability of combination of Nivolumab and Ipilimumab will be studied in patients with 3 different types of cancers in 3 parts of the study, as shown below:

Part 1 - Neoadjuvant Therapy of Breast Cancer;

Part 2 - Therapy of Ovarian Cancer; and

Part 3 - Therapy of Gastric Cancer.

Read the detailed description

Open-Label, Non-Randomization and Safety Run-In: Part 1 of the study is a Phase 2 clinical trial in 20 newly diagnosed patients who have Stage II-III breast cancer, with the primary cancer in place. Parts 2 and 3 of the Study are Phase 2 clinical trials in 20 platinum resistant refractory ovarian cancer (PRROC) and gastric cancer patients, respectively.

Also in all Parts 1, 2 and 3 of the study, there will be a safety run-in involving 3-6 patients. Specifically, the enrollment of patients in each of the 3 parts of the study will begin with 3 patients. If no dose-limiting toxicities (DLTs, defined as toxicity ≥Grade 3) are observed in the first 3 patients during the first cycle, enrollment can continue for the remaining 17 patients. If 1 of the first 3 patients experiences a DLT, the enrollment will be expanded to a total of 6 subjects. If no more than 1 of 6 subjects experiences a DLT, enrollment can continue for the remaining 14 patients. If 2 or more of the first 2-6 subjects experience a DLT, enrollment may be paused. The study data will be reviewed to determine whether alternate dose levels or treatment schedules should be evaluated.

03

Conditions studied

  • Breast Cancer Female
  • Ovarian Cancer
  • Gastric Cancer

Keywords

  • breast cancer
  • ovarian cancer
  • gastric cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria: Patients must meet all inclusion criteria before enrollment:

For Part 1 of the study (i.e., therapy of breast cancer):

A. Stage II-III disease, with primary cancer in place, invasive breast cancer confirmed by core needle (CNB) or incisional biopsy (excisional biopsy is not allowed):

  • fluorescence in situ hybridization (FISH) negative. (Note: Patients who are HER2Neu+3 or HER2Neu+ by FISH are excluded, as there is FDA approved therapy with known clinical benefit in the neoadjuvant setting.)
  • the disease is previously untreated, operable, and intend to undergo surgery (e.g., a mastectomy or lumpectomy) after completion of neoadjuvant therapy
  • the disease must be radiographically measurable in the breast. (radiographically is defined as longest diameter ≥1.0 cm)
  • the disease cannot be axillary disease only (i.e., no identifiable tumor in the breast that is ≥1.0 cm on physical exam or radiographic study)
  • the disease can be multi-centric or bilateral disease, provided the target lesion meets the above eligibility criteria
  • breast cancer patients with lobular and ductal histology will be included. (Note: In patients with clinically positive axillae, histologic confirmation by biopsy or fine-needle aspiration may be performed.) B. Females ≥18 years of age. C. Females of (i.e., women who are pre-menopausal or not surgically sterile) must use effective methods (such as abstinence, intrauterine device [IUD], or double barrier device, and hormonal contraception such as birth control pills cannot be used) during the study and for at least 3 months following completion of the study, and must have a negative serum or urine pregnancy test within 2 weeks prior to treatment initiation.

D. Mentally competent, able to understand and willingness to sign the form.

E. At least 4 weeks must have elapsed from any prior major surgery. The following procedures are not considered major surgical procedure:

  • Obtaining the required research needle biopsies
  • Placement of a radiopaque clip to localize a tumor or tumors for subsequent surgical resection
  • Placement of a port for central venous access
  • Fine needle aspiration of a prominent or suspicious axillary lymph node
  • Needle biopsy of a clinically or radiographically detected lesion to rule out disease

F. Laboratory values ≤2 weeks must be:

  • Adequate hematology (white blood cell [WBC] ≥3500 cells/mm3 or ≥3.5 bil/L; granulocytes ≥1,000/μL; count ≥100,000 cells/mm3 or ≥100 bil/L; [ANC] ≥1,500 cells/mm3 or ≥1.5 bil/L; and (Hgb) ≥9 g/dL or ≥90 g/L).
  • >30 mL/min.
  • Adequate coagulation ( [INR] must be \<1.5) (Note: Patients on anticoagulant of any type are excluded from the study.) G. Normal (EKG) H. Normal echocardiogram within one year (i.e., echocardiogram does not reveal any abnormal heart valves, chambers, or wall movement).

For Part 2 of the study (i.e., therapy of ovarian cancer):

A. Confirmed diagnosis of unresectable epithelial ovarian, fallopian tube or primary peritoneal cancer. Platinum-resistant disease (Progression-Free-Interval [PFI] being 1-6 months since the last dose of platinum-containing chemotherapy) or platinum- disease (PFI being 0-1 month):

  • the disease is evaluable according to (RECIST) v.1.1 criteria
  • ≤4 lines of prior systemic chemotherapy
  • (ECOG) performance status (PS) ≤1 B. Females ≥18 years of age. C. Mentally competent, able to understand and willingness to sign the informed consent form.

D. At least 3 weeks must have elapsed from any prior major surgery. The following procedures are not considered major surgical procedure:

  • obtaining the required research needle biopsies
  • placement of a radiopaque clip to localize a tumor or tumors for subsequent surgical resection
  • placement of a port for central venous access
  • fine needle aspiration or core biopsy of a prominent or suspicious axillary lymph node
  • needle biopsy of a clinically or radiographically detected lesion to rule out metastatic disease
  • peritoneal tap for ascites

E. Laboratory values ≤2 weeks must be:

  • Adequate hematology (WBC ≥3500 cells/mm3 or ≥3.5 bil/L; granulocytes ≥1,000/μL; platelet count ≥100,000 cells/mm3 or ≥100 bil/L; ANC ≥1,500 cells/mm3 or ≥1.5 bil/L; and Hgb ≥9 g/dL or ≥90 g/L).
  • Adequate coagulation (INR must be \<1.5, or 2-3 if subjects are on anticoagulant of any type).

F. Adequate renal, hepatic and bone marrow function based on screening laboratory assessments. Baseline hematologic studies and chemistry profiles must meet the following criteria:

  • Hgb ≥9 g/dL or 90 g/L
  • hematocrit ≥30%
  • ANC ≥1000 cells/mm3 or 1.0 bil/L
  • platelet count ≥100,000 cells/mm3 or ≥100 bil/L
  • blood urea nitrogen (BUN) \<30 mg/dL
  • creatinine clearance >30 mL/min
  • alkaline phosphatase (ALP), (AST) and alanine aminotransferase (ALT) \<2x (ULN) in patients without known hepatic metastases and \<5x ULN in patients with known hepatic metastases
  • prothrombin time (PT) and activated partial thromboplastin time (aPTT) ≤1.6x ULN unless therapeutically warranted

For Part 3 of the study (i.e., therapy of gastric cancer):

A. Confirmed diagnosis of gastric adenocarcinoma or gastroesophageal junction adenocarcinoma. The disease is unresectable, locally advanced or metastatic. Also:

  • patients are refractory or recurrent from at least one in the metastatic setting, or intolerant to standard therapy
  • the disease is evaluable according to RECIST v.1.1 criteria
  • refractory or recurrent from a prior therapy, or intolerant to standard therapy
  • did not receive neoadjuvant or adjuvant treatment (chemotherapy, radiotherapy, or both) for their disease within the last 6 months
  • ECOG PS ≤1

B. Male or female ≥18 years of age.

C. Females of child-bearing potential (i.e., women who are pre-menopausal or not surgically sterile) must use effective contraceptive methods (such as abstinence, intrauterine device (IUD), or double barrier device, and hormonal contraception such as birth control pills cannot be used) during the study and for at least 3 months following completion of the study, and must have a negative serum or urine pregnancy test within 2 weeks prior to treatment initiation. Males with female partners of child-bearing potential should use effective contraception while on study and for at least 3 months following completion of the study.

D. Mentally competent, able to understand and willingness to sign the informed consent form.

E. At least 3 weeks must have elapsed from any prior major surgery. The following procedures are not considered major surgical procedure:

  • obtaining the required research needle biopsies
  • placement of a radiopaque clip to localize a tumor or tumors for subsequent surgical resection
  • placement of a port for central venous access
  • fine needle aspiration or core biopsy of a prominent or suspicious axillary lymph node
  • needle biopsy of a clinically or radiographically detected lesion to rule out metastatic disease
  • peritoneal tap for ascites

F. Laboratory values ≤2 weeks must be:

  • Adequate hematology (WBC ≥3500 cells/mm3 or ≥3.5 bil/L; granulocytes ≥1,000/μL; platelet count ≥100,000 cells/mm3 or ≥100 bil/L; absolute neutrophil count (ANC) ≥1,500 cells/mm3 or ≥1.5 bil/L; and Hgb ≥9 g/dL or ≥90 g/L).
  • Adequate coagulation (INR must be \<1.5, or 2-3 if subjects are on anticoagulant of any type).

G. Adequate renal, hepatic and bone marrow function based on screening laboratory assessments. Baseline hematologic studies and chemistry profiles must meet the following criteria:

  • Hgb ≥9 g/dL or 90 g/L
  • hematocrit ≥30%
  • ANC ≥1000 cells/mm3 or 1.0 bil/L
  • platelet count ≥100,000 cells/mm3 or ≥100 bil/L
  • BUN \<30 mg/dL
  • creatinine clearance >30 mL/min
  • ALP, AST and ALT \<2x ULN in patients without known hepatic metastases and \<5x ULN in patients with known hepatic metastases
  • PT and aPTT ≤1.6x ULN unless therapeutically warranted

Exclusion Criteria: Patients with any of the following characteristics will be excluded:

For Parts 1, 2 and 3 of the study (i.e., neoadjuvant therapy of breast cancer and therapies of ovarian cancer and gastric cancer, respectively):

A. Serious medical illness, such as significant cardiac disease (e.g. symptomatic congestive heart failure, unstable angina pectoris, symptomatic coronary artery disease, myocardial infarction within the past 6 months, uncontrolled or symptomatic cardiac arrhythmia, or Class III or IV), or severe debilitating pulmonary disease, that would potentially increase patients' risk for toxicity

B. Arterial thrombotic event, stroke, or transient ischemia attack within the past 12 months

C. Uncontrolled hypertension (systolic blood pressure >160 mm Hg or diastolic blood pressure >90 mm Hg), or peripheral vascular disease ≥grade 2

D. Active central nervous system (CNS), epidural tumor or metastasis, or .

E. Any active uncontrolled bleeding, or a bleeding diathesis.

F. Evidence of active infection during screening, and any acute therapy needs to be completed within 7 days prior to enrollment.

G. Patients with known (HIV) infection, known active viral hepatitis A, B and C, or known history of tuberculosis, even if treated and in remission. (Noninfectious liver disease is allowed, i.e., NASH or cirrhosis classes A and B, but not C.)

H. Serious or non-healing wound, skin ulcer, or non-healing bone fracture

I. Abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the past 6 months.

J. A history of colitis.

K. Albumin \<2.5 g/dL or \<25 g/L.

L. Any condition or abnormality which may, in the opinion of the investigator, compromise the safety of patients.

M. Unwilling or unable to follow protocol requirements.

N. Patients receiving any other standard or treatment for their cancer, or any other investigational agent for any indication within the past 3 weeks prior to participating in the study.

O. Requirement for immediate palliative treatment of any kind including surgery and radiation.

P. Subjects with diseases, except if they have had adrenal or pituitary insufficiency and are well on replacement therapy (Note: diabetes mellitus, vitiligo, and residual hypothyroidism due to autoimmune thyroiditis are allowed.)

Q. Patients on . (Patients with CNS metastases on low dose steroids prior to the study must be off steroids for at least 4 weeks and must be stable with magnetic resonance imaging (MRI) demonstrating stability over 8 weeks prior to enrollment.)

R. Any within 30 days prior to the start of therapy (Note: Seasonal flu vaccine is acceptable.)

S. Known to OPDIVO or YERVOY, or to their .

T. For Parts 2 and 3 of the study (i.e., or ovarian cancer and gastric cancer patients, respectively) - requirement of permanent or frequent (i.e., once per week) external drainages within two weeks prior to enrollment.

Terms in these criteria, in plain language(28)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
5 participants (actual)

Study arms

  • Experimental
    Neoadjuvant Breast Cancer

    Newly diagnosed patients who have Stage II-III breast cancer, with the primary cancer in place. These patients have not received prior therapy for their breast cancer and intend to undergo surgery after completion of investigational neoadjuvant therapy. Each patient will be treated with two 6-week treatment cycles of Nivolumab 240 mg administered by intravenous (IV) infusion over 30 minutes and Ipilimumab 1 mg/kg administered by IV infusion over 30 minutes. Nivolumab is given every two weeks (q2w) whereas Ipilimumab is given every 6 weeks (q6w), both starting on Day 1. Accordingly, Nivolumab and Ipilimumab are given on the same day on Days 1 and 43. On these days, Ipilimumab is to be given immediately after Nivolumab.

    Biological: Nivolumab · Biological: Ipilimumab

  • Experimental
    Platinum-resistant ovarian cancer

    Platinum-resistant/refractory ovarian cancer (PRROC) patients. Each patient will be treated with four 6-week treatment cycles of Nivolumab 240 mg administered by IV infusion over 30 minutes and Ipilimumab 1 mg/kg administered by IV infusion over 30 minutes. Nivolumab is given q2w whereas Ipilimumab is given q6w, both starting on Day 1. Accordingly, Nivolumab and Ipilimumab are given on the same day on Days 1, 43, 85 and 127. On these days, Ipilimumab is to be given immediately after Nivolumab.

    Biological: Nivolumab · Biological: Ipilimumab

  • Experimental
    Advanced gastric cancer patients

    Advanced gastric cancer patients who are recurrent/refractory to a prior therapy not involving herceptin. Each patient will be treated with four 6-week treatment cycles of Nivolumab and Ipilimumab . Nivolumab is given q2w whereas Ipilimumab is given q6w, both starting on Day 1. Accordingly, Nivolumab and Ipilimumab are given on the same day on Days 1, 43, 85 and 127. On these days, Ipilimumab is to be given immediately after Nivolumab.

    Biological: Nivolumab · Biological: Ipilimumab

Interventions

  • BiologicalNivolumab

    Nivolumab 240 mg administered by IV infusion over 30 minutes

    Also known as: OPDIVO

  • BiologicalIpilimumab

    Ipilimumab 1 mg/kg administered by IV infusion over 30 minutes.

    Also known as: YERVOY

06

What researchers measure

Primary outcomes

  1. Number of participants with treatment-related adverse events as assessed by CTCAE v4.0

    For all 3 parts of the study - Adverse changes in blood work and urinalysis and appearance of adverse events during and after treatment in patients will be assessed

    Time frame: 1 year

  2. Clinical Response

    Part 1 of the Study in Breast Cancer Patients - Clinical response of the investigational neoadjuvant therapy based on pathological Complete Response (pCR) rate; Part 2 of the Study in Ovarian Cancer Patients - Clinical response of the investigational therapy based on Best Objective Response (BOR) and overall response rate (ORR); and Part 3 of the Study in Gastric Cancer Patients - Clinical response of the investigational therapy based on Best Objective Response (BOR) and overall response rate (ORR)

    Time frame: 2 years

Secondary outcomes

  1. Part 1 of the Study (Neoadjuvant Therapy of Breast Cancer) - BCT

    Changes in Breast Conservation Therapy (BCT) rate is the percentage of subjects who are eligible for BCT according to the clinico-radiographic criteria by Morrow et al. (2002)

    Time frame: 2 years

  2. Part 1 of the Study (Neoadjuvant Therapy of Breast Cancer) - Possible predictive biomarkers

    Possible predictive biomarkers such as, but not limited to, Tumor Infiltrating Lymphocyte (TIL), and Tumor Infiltrating Myeloid Cells (TIMC), and immunological biomarkers in blood

    Time frame: 2 years

  3. Part 1 of the Study (Neoadjuvant Therapy of Breast Cancer) - Status of PD-L1, PDL-2, and PD-1 in tumor tissues before vs. after investigational neoadjuvant therapy

    Status of Programmed-Death-Ligand 1 (PD-L1), Programmed-Death-Ligand 2 (PDL-2) and Programmed-Death Receptor-1 (PD-1) in tumor tissues before vs. after investigational neoadjuvant therapy

    Time frame: 2 years

  4. Part 1 of the Study (Neoadjuvant Therapy of Breast Cancer) - Possible transition of Th2 to Th1 in the tumor

    Possible transition of T helper cell type 2 (Th2) to T helper cell type 1 (Th1) in the tumor microenvironment to favor anti-tumor activity

    Time frame: 2 years

  5. Part 1 of the Study (Neoadjuvant Therapy of Breast Cancer) - BOR and ORR

    Best Objective Response (BOR) and Overall Response Rate (ORR) assessed after investigational neoadjuvant therapy and before surgery

    Time frame: 2 years

  6. Part 1 of the Study (Neoadjuvant Therapy of Breast Cancer) - PFS

    Progression Free Survival (PFS) assessed after surgery

    Time frame: 2 years

  7. Part 2 of the Study (Therapy of Ovarian Cancer) and Part 3 of the Study (Therapy of Gastric Cancer) - DOR

    Duration of Response (DOR)

    Time frame: 2 years

  8. Part 2 of the Study (Therapy of Ovarian Cancer) and Part 3 of the Study (Therapy of Gastric Cancer) - OS

    Overall Survival (OS)

    Time frame: 2 years

  9. Part 2 of the Study (Therapy of Ovarian Cancer) and Part 3 of the Study (Therapy of Gastric Cancer) - Recurrence rate

    Recurrence rate of disease

    Time frame: 2 years

Other outcomes

  1. Part 1 of the Study (Neoadjuvant Therapy of Breast Cancer) - Tumor Genomics and Biomarkers

    To assess the baseline values, and potential correlations between the baseline values with response to the investigational neoadjuvant therapy of the following parameters in tumor tissues: (1) Next Generation Sequencing (NGS), tumor mutation, tumor mutation burden, and Loss of Heterozygocity (LOH), and (2) Tissue biomarkers by reverse phase protein microassays (RPPM) and gene expression profile

    Time frame: 2 years

  2. Part 1 of the Study (Neoadjuvant Therapy of Breast Cancer) - Circulating DNA

    To explore circulating DNA (liquid biopsy) mutations at baseline and after surgery, and possible correlation with treatment response

    Time frame: 2 years

  3. Part 1 of the Study (Neoadjuvant Therapy of Breast Cancer) - Immune Cell Activation Markers

    To correlate changes in immune cell activation markers such as CD3, CD8, CD16, CD45, and/or CD86 expression in tumor tissues and in peripheral blood immune cells at baseline, mid-treatment and at completion of investigational neoadjuvant therapy with objective response and treatment outcome

    Time frame: 2 years

  4. Part 1 of the Study (Neoadjuvant Therapy of Breast Cancer) - Tumor Biomarkers

    To study biomarkers at baseline, mid-treatment, and at completion of investigational neoadjuvant therapy, in serial tumor biopsies to study non-responders in comparison to best responders

    Time frame: 2 years

  5. Part 1 of the Study (Neoadjuvant Therapy of Breast Cancer) - Additional Immune Cell Biomarkers

    To study immune cell activation markers such as CD3, CD8, CD16, CD45, and/or CD86 expression, T-cell immunoglobulin and ITIM domain (TIGIT) and poliovirus receptor (PVR) in blood at baseline, mid-treatment, and at completion of investigational neoadjuvant therapy, and potential correlation to treatment effect of investigational neoadjuvant therapy

    Time frame: 2 years

  6. Part 1 of the Study (Neoadjuvant Therapy of Breast Cancer) - PD-L1

    To assess serum soluble PD-L1 levels before and after investigational neoadjuvant therapy, and potential correlation to treatment effect of investigational neoadjuvant therapy

    Time frame: 2 years

  7. Part 1 of the Study (Neoadjuvant Therapy of Breast Cancer) - Time to Response

    To evaluate time to tumor response

    Time frame: 2 years

  8. Part 1 of the Study (Neoadjuvant Therapy of Breast Cancer) - Tumor Volume vs. Pathological Responses

    To assess possible correlation of tumor volumetric changes from different imaging modalities vs. pathological response (optional)

    Time frame: 2 years

  9. Part 1 of the Study (Neoadjuvant Therapy of Breast Cancer) - NK

    To assess Natural Killer (NK) cells in tumor tissues before and after investigational neoadjuvant therapy for potential changes, and to correlate with treatment responses (optional)

    Time frame: 2 years

  10. Part 1 of the Study (Neoadjuvant Therapy of Breast Cancer) - Recurrence rate (optional)

    To assess tumor recurrence rate (optional)

    Time frame: 2 years

  11. Part 1 of the Study (Neoadjuvant Therapy of Breast Cancer) - CTC

    To collect and store Circulating Tumor Cells (CTC) for possible future studies of involved biomolecular and immunological pathways (optional)

    Time frame: 2 years

  12. Part 2 of the Study (Therapy of Ovarian Cancer) and Part 3 of the Study (Therapy of Gastric Cancer) - Circulating DNA

    To explore circulating DNA (liquid biopsy) mutations at baseline and completion of investigational therapy, and possible correlation with treatment response

    Time frame: 2 years

  13. Part 2 of the Study (Therapy of Ovarian Cancer) and Part 3 of the Study (Therapy of Gastric Cancer) - TIGIT and PVR

    To study TIGIT and PVR in blood at baseline, mid-treatment, and at completion of investigational therapy, and potential correlation to effect of investigational therapy

    Time frame: 2 years

  14. Part 2 of the Study (Therapy of Ovarian Cancer) and Part 3 of the Study (Therapy of Gastric Cancer) - PD-L1

    To assess serum soluble PD-L1 levels at baseline, mid-treatment, and at completion of investigational therapy, and potential correlation to investigational therapy

    Time frame: 2 years

  15. Part 2 of the Study (Therapy of Ovarian Cancer) and Part 3 of the Study (Therapy of Gastric Cancer) - Genomics (Optional)

    Optional - To assess the baseline values, and potential correlations between the baseline values with response to the investigational therapy of the following parameters in tumor tissues: PD-L1 expression, NGS, tumor mutations, tumor mutation burden, and LOH; and Tissue biomarkers by RPPM

    Time frame: 2 years

  16. Part 2 of the Study (Therapy of Ovarian Cancer) and Part 3 of the Study (Therapy of Gastric Cancer) - Immune Cell Activation Markers

    To correlate changes in immune cell activation markers such as CD3, CD8, CD16, CD45, and/or CD86 expression in tumor tissues (optional) and in peripheral blood immune cells at baseline, mid-treatment and at completion of investigational therapy with objective response and treatment outcome

    Time frame: 2 years

  17. Part 2 of the Study (Therapy of Ovarian Cancer) and Part 3 of the Study (Therapy of Gastric Cancer) - Tumor Burden

    To assess tumor burden by RECIST criteria at every cycle and after completion of investigational therapy.

    Time frame: 2 years

  18. Part 2 of the Study (Therapy of Ovarian Cancer) - CA-125

    To evaluate the CA-125 response rate (Gynecologic Cancer InterGroup \[GCIG\] criteria) at every cycle and after completion of investigational therapy.

    Time frame: 2 years

  19. Part 2 of the Study (Therapy of Ovarian Cancer) and Part 3 of the Study (Therapy of Gastric Cancer) - Time to Response

    To evaluate time to response

    Time frame: 2 years

  20. Part 2 of the Study (Therapy of Ovarian Cancer) and Part 3 of the Study (Therapy of Gastric Cancer) - CTC

    To collect and store CTC at baseline, mid-treatment and at completion of investigational therapy for possible future studies of involved biomolecular and immunological pathways (optional)

    Time frame: 2 years

  21. Part 2 of the Study (Therapy of Ovarian Cancer) and Part 3 of the Study (Therapy of Gastric Cancer) - PRO

    Patient-reported outcome (PRO) using the European Organization for Research

    Time frame: 2 years

  22. Part 2 of the Study (Therapy of Ovarian Cancer) and Part 3 of the Study (Therapy of Gastric Cancer) QOL-c30

    Quality of life questionnaires using QLQ-C30

    Time frame: 2 years

  23. Part 2 of the Study (Therapy of Ovarian Cancer) and Part 3 of the Study (Therapy of Gastric Cancer) - QLQ-OV28

    Quality of life questionnaires using QLQ-OV28

    Time frame: 2 years

07

Study locations

1 site
  • Hoffman Oncology
    Bronx, New York 10469, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2018 to primary completion in May 2019, 15 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 20, 2017
First posted
Nov 17, 2017
StartActual
Feb 14, 2018
Primary completionActual
May 29, 2019
CompletionActual
May 29, 2019
Last update
Nov 9, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 9, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03342417
Lead sponsor
ExcellaBio LLC
Responsible party
Sponsor
First posted
Nov 17, 2017
Start date
Feb 14, 2018
Primary completion
May 29, 2019
Completion
May 29, 2019
Last update
Nov 9, 2021

Study contacts

Anthony Hoffman, MD
principal investigator · ExcellaBio LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Nivolumab · Ipilimumab

Start the discussion